AbbVie Inc. (ABBV): Total Assets
$133.96B
As of 2025-12-31
$135.12B
As of 2026-06-30
-1.2%
3-year compound annual growth
-2.3%
5-year compound annual growth
+9.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $133.96B | -0.9% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $135.16B | +0.3% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $134.71B | -2.9% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $138.81B | -5.3% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $146.53B | -2.7% | 2023-02-17, Balance as of period end |
| 2020-12-31 | $150.56B | +69.0% | 2022-02-18, Balance as of period end |
| 2019-12-31 | $89.11B | +50.1% | 2021-02-19, Balance as of period end |
| 2018-12-31 | $59.35B | -16.2% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $70.79B | +7.1% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $66.10B | +24.6% | 2018-02-16, Balance as of period end |
| 2015-12-31 | $53.05B | +92.8% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $27.51B | -5.8% | 2016-02-19, Balance as of period end |
| 2013-12-31 | $29.20B | +8.1% | 2015-02-20, Balance as of period end |
| 2012-12-31 | $27.01B | n/a | 2014-02-21, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $133.96B | -0.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $40.75B | +3.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $40.56B | +7.4% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗